Fully Underwritten A$50.7 Million Entitlement Offer
Filed with ASX · · 4 pages · English
In the deck
Earlier from Mesoblast
- Potential For Accelerated Market Entry In Advanced CHF
- Positive Results of MSB Therapy in Osteoarthritis Published
- Mesoblast RA Results Presented At EULAR Congress
- MSB Provides Q3 Operational Highlights and Financial Results
- Third Quarter Financial Results On Form 6-K
Later from Mesoblast
- Underwritten A$50.7M Raise Closes Institutional Allocation
- Retail Entitlement Offer
- Mesoblast Corporate Updates at Healthcare Conferences
- End-Stage Heart Failure Trial Completes Enrollment
- RA Phase 2 Trial Results Presented At ACR Annual Meeting
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast